Browsing Category
Pharma Industry News
4750 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Zai Lab stock rallies on regulatory optimism in China’s oncology sector
Zai Lab stock jumps 7.6% on China FDA review optimism for its oncology drugs, as cross-border biotech sentiment improves. Read the full investor analysis.
Be Biopharma unveils promising preclinical data for BE-102 B cell therapy targeting hypophosphatasia
In a notable advancement for genetic bone disorder therapies, Be Biopharma Inc. has presented new preclinical data for…
Tonix Pharmaceuticals stock up over 20%: Can TNX-102 SL and TNX-1700 fuel a turnaround in 2025?
Tonix Pharmaceuticals surged 21% despite deep losses, as retail traders bet on TNX-102 SL’s FDA nod and cancer pipeline momentum. Read the full story.
ACADIA Pharmaceuticals stock surges 26% after key patent win and robust Q1 results: What’s driving investor optimism?
Find out why ACADIA Pharmaceuticals stock soared 26% on May 16, 2025, after a favorable court ruling and strong earnings—plus what’s next for its CNS pipeline.
Alembic Pharmaceuticals receives FDA final approval for Rivaroxaban Tablets across all strengths
Alembic Pharmaceuticals secures USFDA approval for Rivaroxaban tablets in all strengths. Find out how this opens a $8.5B market opportunity in FY26.
Lupin gets US FDA nod for generic Xarelto; Eyes $8bn anticoagulant market
Lupin wins FDA approval for generic Xarelto, unlocking access to a USD 8 billion U.S. anticoagulant market. Find out what this means for investors and rivals.
FDA grants orphan drug exclusivity to Mesoblast’s Ryoncil for pediatric SR-aGvHD
Find out how Mesoblast's FDA approval for Ryoncil in pediatric SR-aGvHD sets a new benchmark in stem cell therapy and market exclusivity strategy.
Chimeric Therapeutics reports early success in frontline cell therapy for AML in ADVENT-AML Phase 1B trial
Chimeric Therapeutics reports promising early results in its ADVENT-AML trial, with 2 of 3 patients showing remission. Find out how CHM is advancing cell therapy.
Regencell Bioscience surges 9.86% amid low-float frenzy, but fundamentals remain
Regencell Bioscience (RGC) jumps 9.86% to $342.99 on low volume. Find out what’s driving the surge—and why institutions are still staying away.
Lupin reports robust FY25 earnings with 71% profit growth and 600% dividend payout
Lupin posts 71% profit growth in FY25 with 600% dividend and strong U.S. performance. Find out how the pharma major is transforming its global footprint.